TrialCancer2012

Phase 2 randomized study of p53 antisense oligonucleotide (cenersen) plus idarubicin with or without cytarabine in refractory and relapsed acute myeloid leukemia.

Jorge Cortes et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.